天堂网亚洲,天天操天天搞,91视频高清,菠萝蜜视频在线观看入口,美女视频性感美女视频,95丝袜美女视频国产,超高清美女视频图片

ChemicalBook >> journal list >> Pharmacological Reviews >>article
Pharmacological Reviews

Pharmacological Reviews

IF: 19.3
Download PDF

Drugs for Insomnia beyond Benzodiazepines: Pharmacology, Clinical Applications, and Discovery.

Published:1 April 2018 DOI: 10.1124/pr.117.014381 PMID: 29487083
Tobias Atkin, Stefano Comai, Gabriella Gobbi

Abstract

Although the GABAergic benzodiazepines (BZDs) and Z-drugs (zolpidem, zopiclone, and zaleplon) are FDA-approved for insomnia disorders with a strong evidence base, they have many side effects, including cognitive impairment, tolerance, rebound insomnia upon discontinuation, car accidents/falls, abuse, and dependence liability. Consequently, the clinical use of off-label drugs and novel drugs that do not target the GABAergic system is increasing. The purpose of this review is to analyze the neurobiological and clinical evidence of pharmacological treatments of insomnia, excluding the BZDs and Z-drugs. We analyzed the melatonergic agonist drugs, agomelatine, prolonged-release melatonin, ramelteon, and tasimelteon; the dual orexin receptor antagonist suvorexant; the modulators of the α2δ subunit of voltage-sensitive calcium channels, gabapentin and pregabalin; the H1 antagonist, low-dose doxepin; and the histamine and serotonin receptor antagonists, amitriptyline, mirtazapine, trazodone, olanzapine, and quetiapine. The pharmacology and mechanism of action of these treatments and the evidence-base for the use of these drugs in clinical practice is outlined along with novel pipelines. There is evidence to recommend suvorexant and low-dose doxepin for sleep maintenance insomnia; there is also sufficient evidence to recommend ramelteon for sleep onset insomnia. Although there is limited evidence for the use of the quetiapine, trazodone, mirtazapine, amitriptyline, pregabalin, gabapentin, agomelatine, and olanzapine as treatments for insomnia disorder, these drugs may improve sleep while successfully treating comorbid disorders, with a different side effect profile than the BZDs and Z-drugs. The unique mechanism of action of each drug allows for a more personalized and targeted medical management of insomnia.

Substances (12)

Related products
Procduct Name CAS Molecular Formula Supplier Price
Pregabalin 148553-50-8 C8H17NO2 866 suppliers $44.00-$2480.00
Gabapentin 60142-96-3 C9H17NO2 836 suppliers $9.35-$775.00
Agomelatine 138112-76-2 C15H17NO2 627 suppliers $5.00-$2500.00
Olanzapine 132539-06-1 C17H20N4S 562 suppliers $32.00-$1686.30
Ramelteon 196597-26-9 C16H21NO2 396 suppliers $9.00-$1400.00
Mirtazapine 85650-52-8 C17H19N3 323 suppliers $5.00-$2240.00
Quetiapine 111974-69-7 C21H25N3O2S 206 suppliers $25.00-$1152.00
Tasimelteon 609799-22-6 C15H19NO2 154 suppliers $28.00-$1854.00
Trazodone 19794-93-5 C19H22ClN5O 125 suppliers $185.00-$732.00
Amitriptyline 50-48-6 C20H23N 102 suppliers Inquiry

Similar articles

IF:4.6

Clinical pharmacology of axitinib.

Clinical Pharmacokinetics Ying Chen, Michael A Tortorici,etc Published: 1 September 2013
IF:4.6

Tenofovir disoproxil fumarate: clinical pharmacology and pharmacokinetics.

Clinical Pharmacokinetics Brian P Kearney, John F Flaherty,etc Published: 1 January 2004
IF:2.4

Azelastine hydrochloride: a review of pharmacology, pharmacokinetics, clinical efficacy and tolerability.

Current Medical Research and Opinion Jonathan A Bernstein,etc Published: 1 October 2007